University of Glasgow
gla.ac.ukTotal trials
140
Active
18
Phase 3
7
Total enrollment
562,344
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Beta-glucan addition to a restricted calorie of meal replacements and carbohydrate diet. | — | — | — | — | — | 1 | |
| Cellulose (Placebo) addition to a restricted calorie of meal replacements and carbohydrate diet. | — | — | — | — | — | 1 |
Next readouts
- 2025-01-31
Top conditions
- Healthy9
- Sarcopenia6
- Exercise5
- Asthma5
- Spinal Cord Injury4
- Covid193
- Overweight and Obesity3
- Unspecified Adult Solid Tumor, Protocol Specific3
Frequently asked questions about University of Glasgow
- How many clinical trials does University of Glasgow have on ClinicalTrials.gov?
- University of Glasgow is listed as the lead sponsor on 140 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Glasgow's trials are in Phase 3?
- 7 of University of Glasgow's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does University of Glasgow focus on?
- University of Glasgow's most-studied conditions on ClinicalTrials.gov are Healthy, Sarcopenia, Exercise, Asthma, Spinal Cord Injury.
- When are University of Glasgow's next clinical trial readouts?
- University of Glasgow has 1 upcoming primary-completion readout tracked here; the soonest is “Impact of Beta-glucan Supplementation During Calorie and Carbohydrate-restricted Diet on Body Weight and Body Fat Loss, Appetite, and Gastrointestinal Appetite Hormones.”, expected around 2025-01-31.